Abstract 5377: Decitabine sensitizes diffuse large B cell lymphoma cells to venetoclax
Matthew S. Davids(Dana-Farber Cancer Institute), May C. Collins(Dana-Farber Cancer Institute), Liam Hackett(Dana-Farber Cancer Institute), Fen Zhu(Dana-Farber Cancer Institute), Stephen Jun Fei Chong(Harvard University), Jennifer L. Crombie(Dana-Farber Cancer Institute)
Cited by 0
Related Papers
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
|Journal of Clinical Oncology|2017|752
Small molecules, big impact: 20 years of targeted therapy in oncology
|The Lancet|2020|606
Ipilimumab for Patients with Relapse after Allogeneic Transplantation
|New England Journal of Medicine|2016|595